Supplementary Data from A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline &lt;i&gt;BRCA1/2&lt;/i&gt; Mutations (ABRAZO)